US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
EP0092918B1
(en)
|
1982-04-22 |
1988-10-19 |
Imperial Chemical Industries Plc |
Continuous release formulations
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
US5128326A
(en)
|
1984-12-06 |
1992-07-07 |
Biomatrix, Inc. |
Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
|
DE3675588D1
(de)
|
1985-06-19 |
1990-12-20 |
Ajinomoto Kk |
Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・2・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
ATE120761T1
(de)
|
1987-05-21 |
1995-04-15 |
Creative Biomolecules Inc |
Multifunktionelle proteine mit vorbestimmter zielsetzung.
|
US5336603A
(en)
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
KR900005995A
(ko)
|
1988-10-31 |
1990-05-07 |
우메모또 요시마사 |
변형 인터류킨-2 및 그의 제조방법
|
EP0394827A1
(en)
|
1989-04-26 |
1990-10-31 |
F. Hoffmann-La Roche Ag |
Chimaeric CD4-immunoglobulin polypeptides
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
AU6430190A
(en)
|
1989-10-10 |
1991-05-16 |
Pitman-Moore, Inc. |
Sustained release composition for macromolecular proteins
|
WO1991006570A1
(en)
|
1989-10-25 |
1991-05-16 |
The University Of Melbourne |
HYBRID Fc RECEPTOR MOLECULES
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
WO1991006287A1
(en)
|
1989-11-06 |
1991-05-16 |
Enzytech, Inc. |
Protein microspheres and methods of using them
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5349053A
(en)
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
DK0564531T3
(da)
|
1990-12-03 |
1998-09-28 |
Genentech Inc |
Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
|
DE69123241T2
(de)
|
1990-12-14 |
1997-04-17 |
Cell Genesys Inc |
Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
LU91067I2
(fr)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
US5844095A
(en)
|
1991-06-27 |
1998-12-01 |
Bristol-Myers Squibb Company |
CTLA4 Ig fusion proteins
|
WO1993006213A1
(en)
|
1991-09-23 |
1993-04-01 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
DE69233528T2
(de)
|
1991-11-25 |
2006-03-16 |
Enzon, Inc. |
Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
|
US5869619A
(en)
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
US5766886A
(en)
|
1991-12-13 |
1998-06-16 |
Xoma Corporation |
Modified antibody variable domains
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
CA2372813A1
(en)
|
1992-02-06 |
1993-08-19 |
L.L. Houston |
Biosynthetic binding protein for cancer marker
|
US5912015A
(en)
|
1992-03-12 |
1999-06-15 |
Alkermes Controlled Therapeutics, Inc. |
Modulated release from biocompatible polymers
|
US5447851B1
(en)
|
1992-04-02 |
1999-07-06 |
Univ Texas System Board Of |
Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
|
GB9225453D0
(en)
|
1992-12-04 |
1993-01-27 |
Medical Res Council |
Binding proteins
|
US5837242A
(en)
|
1992-12-04 |
1998-11-17 |
Medical Research Council |
Multivalent and multispecific binding proteins, their manufacture and use
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
US7435802B2
(en)
*
|
1994-01-25 |
2008-10-14 |
Elan Pharaceuticals, Inc. |
Humanized anti-VLA4 immunoglobulins
|
IL108501A
(en)
|
1994-01-31 |
1998-10-30 |
Mor Research Applic Ltd |
Antibodies and pharmaceutical compositions containing them
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
US5605793A
(en)
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
US5834252A
(en)
|
1995-04-18 |
1998-11-10 |
Glaxo Group Limited |
End-complementary polymerase reaction
|
JPH07291996A
(ja)
|
1994-03-01 |
1995-11-07 |
Yuu Honshiyo |
ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするdna、そのdnaからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
|
GB9415379D0
(en)
|
1994-07-29 |
1994-09-21 |
Smithkline Beecham Plc |
Novel compounds
|
MX9700764A
(es)
|
1994-07-29 |
1997-05-31 |
Smithkline Beecham Plc |
Compuestos novedosos.
|
CA2207961A1
(en)
|
1995-01-05 |
1996-07-11 |
Robert J. Levy |
Surface-modified nanoparticles and method of making and using same
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
WO1996022024A1
(en)
|
1995-01-17 |
1996-07-25 |
Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
CA2230494A1
(en)
|
1995-08-31 |
1997-03-06 |
Alkermes Controlled Therapeutics Inc. |
Composition for sustained release of an agent
|
US5723125A
(en)
|
1995-12-28 |
1998-03-03 |
Tanox Biosystems, Inc. |
Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
|
CA2249195A1
(en)
|
1996-03-18 |
1997-09-25 |
Board Of Regents, The University Of Texas System |
Immunoglobin-like domains with increased half lives
|
GB9701425D0
(en)
|
1997-01-24 |
1997-03-12 |
Bioinvent Int Ab |
A method for in vitro molecular evolution of protein function
|
US5989463A
(en)
|
1997-09-24 |
1999-11-23 |
Alkermes Controlled Therapeutics, Inc. |
Methods for fabricating polymer-based controlled release devices
|
SE512663C2
(sv)
|
1997-10-23 |
2000-04-17 |
Biogram Ab |
Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
|
US20060029600A1
(en)
*
|
1998-01-21 |
2006-02-09 |
Elan Pharmaceuticals, Inc. |
Treatment of viral encephalitis by agents blocking alpha-VLA-4 integrin function
|
CA2323757C
(en)
|
1998-04-02 |
2011-08-02 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
EP1141024B1
(en)
|
1999-01-15 |
2018-08-08 |
Genentech, Inc. |
POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
WO2001014557A1
(en)
|
1999-08-23 |
2001-03-01 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
CA2414331C
(en)
|
2000-06-28 |
2011-11-29 |
Genetics Institute, Llc. |
Pd-l2 molecules: novel pd-1 ligands and uses therefor
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
BR0208637A
(pt)
|
2001-04-02 |
2004-12-07 |
Wyeth Corp |
Pd-1, um receptor para b7-4, e usos dos mesmos
|
WO2003011911A1
(en)
*
|
2001-07-31 |
2003-02-13 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to pd-1
|
ES2327905T3
(es)
|
2001-10-01 |
2009-11-05 |
Dyax Corp. |
Vectores de presentacion eucariotas multi-cadena y usos de los mismos.
|
US20040005709A1
(en)
|
2001-10-24 |
2004-01-08 |
Hoogenboom Henricus Renerus Jacobus Mattheus |
Hybridization control of sequence variation
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
NZ556507A
(en)
|
2002-06-03 |
2010-03-26 |
Genentech Inc |
Synthetic antibody phage libraries
|
PT1537878E
(pt)
|
2002-07-03 |
2010-11-18 |
Ono Pharmaceutical Co |
Composições de imunopotenciação
|
TWI323265B
(en)
*
|
2002-08-06 |
2010-04-11 |
Glaxo Group Ltd |
Antibodies
|
AU2003288675B2
(en)
|
2002-12-23 |
2010-07-22 |
Medimmune Limited |
Antibodies against PD-1 and uses therefor
|
EP2270051B1
(en)
|
2003-01-23 |
2019-05-15 |
Ono Pharmaceutical Co., Ltd. |
Antibody specific for human PD-1 and CD3
|
GB0400440D0
(en)
|
2004-01-09 |
2004-02-11 |
Isis Innovation |
Receptor modulators
|
PL1810026T3
(pl)
|
2004-10-06 |
2018-08-31 |
Mayo Foundation For Medical Education And Research |
B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego
|
KR101498834B1
(ko)
|
2005-05-09 |
2015-03-05 |
오노 야꾸힝 고교 가부시키가이샤 |
예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
|
NZ564243A
(en)
|
2005-06-08 |
2011-03-31 |
Dana Farber Cancer Inst Inc |
Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1) pathway
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US8603930B2
(en)
|
2005-10-07 |
2013-12-10 |
Sulzer Metco (Us), Inc. |
High-purity fused and crushed zirconia alloy powder and method of producing same
|
SG172698A1
(en)
|
2006-06-12 |
2011-07-28 |
Trubion Pharmaceuticals Inc |
Single-chain multivalent binding proteins with effector function
|
US9023993B2
(en)
|
2006-10-20 |
2015-05-05 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient
|
EP2102241A2
(en)
|
2006-12-15 |
2009-09-23 |
Ablynx N.V. |
Amino acid sequences that modulate the interaction between cells of the immune system
|
JP2010520748A
(ja)
|
2007-02-20 |
2010-06-17 |
アナプティスバイオ インコーポレイティッド |
体細胞超変異系
|
US20100267934A1
(en)
|
2007-05-31 |
2010-10-21 |
Genmab A/S |
Stable igg4 antibodies
|
DK2170959T3
(da)
|
2007-06-18 |
2014-01-13 |
Merck Sharp & Dohme |
Antistoffer mod human programmeret dødsreceptor pd-1
|
WO2009024531A1
(en)
|
2007-08-17 |
2009-02-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating and diagnosing hematologic malignancies
|
AU2008320987B2
(en)
|
2007-11-13 |
2014-04-17 |
Teva Biopharmaceuticals Usa, Inc. |
Humanized antibodies against TL1A
|
ES2639857T3
(es)
|
2008-02-11 |
2017-10-30 |
Cure Tech Ltd. |
Anticuerpos monoclonales para el tratamiento del tumor
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
AU2009228158B2
(en)
|
2008-03-27 |
2014-02-27 |
Zymogenetics, Inc. |
Compositions and methods for inhibiting PDGFRbeta and VEGF-A
|
US8927697B2
(en)
|
2008-09-12 |
2015-01-06 |
Isis Innovation Limited |
PD-1 specific antibodies and uses thereof
|
JP5794917B2
(ja)
|
2008-09-12 |
2015-10-14 |
アイシス・イノベーション・リミテッドIsis Innovationlimited |
Pd−1特異抗体およびその使用
|
HUE030807T2
(en)
|
2008-09-26 |
2017-05-29 |
Dana Farber Cancer Inst Inc |
Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications
|
JP5840494B2
(ja)
|
2008-10-02 |
2016-01-06 |
エマージェント プロダクト デベロップメント シアトル, エルエルシー |
Cd86アンタゴニストの多標的結合タンパク質
|
SG10201610247QA
(en)
|
2008-12-03 |
2017-02-27 |
Genmab As |
Antibody variants having modifications in the constant region
|
WO2010089411A2
(en)
|
2009-02-09 |
2010-08-12 |
Universite De La Mediterranee |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
US10909545B2
(en)
*
|
2009-07-24 |
2021-02-02 |
Oracle International Corporation |
Interactive store design interface based system
|
WO2011100841A1
(en)
|
2010-02-16 |
2011-08-25 |
Valorisation-Recherche, Limited Partnership |
Pd-1 modulation and uses thereof for modulating hiv replication
|
WO2011110604A1
(en)
|
2010-03-11 |
2011-09-15 |
Ucb Pharma, S.A. |
Pd-1 antibody
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
US20180237525A9
(en)
|
2010-03-26 |
2018-08-23 |
Randolph J. Noelle |
VISTA Agonist and Methods of Use
|
BR112012026403B1
(pt)
|
2010-04-16 |
2022-10-04 |
Biogen Ma Inc |
Molécula de anticorpo recombinante ou um fragmento de ligação a ?4 da mesma e seu uso
|
LT2691112T
(lt)
|
2011-03-31 |
2018-07-25 |
Merck Sharp & Dohme Corp. |
Stabilios antikūnų kompozicijos prieš žmogaus programuojamos mirties receptorių pd-1 ir susiję gydymo būdai
|
DK2699264T3
(en)
*
|
2011-04-20 |
2018-06-25 |
Medimmune Llc |
ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
|
EP2726103B1
(en)
*
|
2011-07-01 |
2018-09-05 |
The Trustees Of The University Of Pennsylvania |
Anti-properdin antibodies and uses thereof
|
CA2840018C
(en)
|
2011-07-24 |
2019-07-16 |
Curetech Ltd. |
Variants of humanized immunomodulatory monoclonal antibodies
|
EP3939613A1
(en)
|
2011-08-11 |
2022-01-19 |
ONO Pharmaceutical Co., Ltd. |
Therapeutic agent for autoimmune diseases comprising pd-1 agonist
|
US9644179B2
(en)
|
2011-11-23 |
2017-05-09 |
The Trustees Of The University Of Pennsylvania |
Use of PDL1 expressing cells to convert T cells into regulatory T cells
|
US20150086584A1
(en)
|
2012-03-22 |
2015-03-26 |
University Of Miami |
Multi-specific binding agents
|
WO2013177102A2
(en)
|
2012-05-21 |
2013-11-28 |
Felder Mitchell S |
Treatment of cancer by manipulating the immune system
|
AU2013277051B2
(en)
|
2012-06-22 |
2018-06-07 |
King's College London |
Novel VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
EP3613765A1
(en)
|
2012-08-03 |
2020-02-26 |
Dana-Farber Cancer Institute, Inc. |
Antibody against repulsive guidance molecule b (rgmb)
|
WO2014116846A2
(en)
|
2013-01-23 |
2014-07-31 |
Abbvie, Inc. |
Methods and compositions for modulating an immune response
|
WO2014121085A1
(en)
|
2013-01-31 |
2014-08-07 |
Thomas Jefferson University |
Pd-l1 and pd-l2-based fusion proteins and uses thereof
|
EP2954327A1
(en)
|
2013-02-07 |
2015-12-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from diffuse large b-cell lymphomas
|
RU2680010C2
(ru)
|
2013-02-26 |
2019-02-14 |
Мемориал Слоан-Кеттеринг Кэнсер Сентер |
Композиции и способы иммунотерапии
|
CN105143257B
(zh)
|
2013-03-15 |
2020-10-27 |
艾伯维生物医疗股份有限公司 |
Fc变体
|
CA2906927C
(en)
|
2013-03-15 |
2021-07-13 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
CN105431449B
(zh)
|
2013-04-05 |
2021-08-24 |
港大科桥有限公司 |
新的pd1同种型及其用于加强免疫应答的用途
|
RS61400B1
(sr)
|
2013-05-02 |
2021-02-26 |
Anaptysbio Inc |
Antitela usmerena protiv programirane smrti-1 (pd-1)
|
CN111423511B
(zh)
|
2013-05-31 |
2024-02-23 |
索伦托药业有限公司 |
与pd-1结合的抗原结合蛋白
|
CA2953287A1
(en)
|
2013-06-19 |
2014-12-24 |
Massachusetts Institute Of Technology |
In vivo targeting of cells with ligand-conjugated particles
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
EP3017048A4
(en)
|
2013-07-01 |
2017-05-17 |
University of Maryland, College Park |
Fc coupled compositions and methods of their use
|
WO2015036394A1
(en)
*
|
2013-09-10 |
2015-03-19 |
Medimmune Limited |
Antibodies against pd-1 and uses thereof
|
WO2015038538A1
(en)
|
2013-09-10 |
2015-03-19 |
Medimmune, Llc |
Compositions and methods for treating sepsis
|
HUE060420T2
(hu)
|
2013-09-13 |
2023-02-28 |
Beigene Switzerland Gmbh |
Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk
|
HUE047194T2
(hu)
|
2013-09-27 |
2020-04-28 |
Hoffmann La Roche |
Anti-PDL1 antitest készítmények
|
US10259875B2
(en)
|
2013-10-01 |
2019-04-16 |
Mayo Foundation For Medical Education And Research |
Methods for treating cancer in patients with elevated levels of BIM
|
CN104558177B
(zh)
|
2013-10-25 |
2020-02-18 |
苏州思坦维生物技术股份有限公司 |
拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
|
EP3071600B1
(en)
*
|
2013-11-20 |
2020-06-17 |
Regeneron Pharmaceuticals, Inc. |
Aplnr modulators and uses thereof
|
SG11201604738TA
(en)
|
2013-12-12 |
2016-07-28 |
Shanghai Hengrui Pharm Co Ltd |
Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
ES2923641T3
(es)
|
2013-12-30 |
2022-09-29 |
Epimab Biotherapeutics Inc |
Inmunoglobulina con Fabs en tándem y usos de la misma
|
US20160130336A1
(en)
|
2013-12-31 |
2016-05-12 |
Development Center For Biotechnology |
Anti-vegf antibodies and use thereof
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
WO2015119841A1
(en)
|
2014-02-05 |
2015-08-13 |
Merck Sharp & Dohme Corp. |
Role of il-23 and pd-1 in autoreactive immune response
|
CN106414723A
(zh)
|
2014-02-10 |
2017-02-15 |
纳维基因股份有限公司 |
细胞调节纳米组合物及使用方法
|
WO2015138600A2
(en)
|
2014-03-11 |
2015-09-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
|
US10519237B2
(en)
|
2014-03-12 |
2019-12-31 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
NZ725006A
(en)
|
2014-03-12 |
2019-11-29 |
Yeda Res & Dev |
Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
|
WO2017042633A2
(en)
|
2015-09-10 |
2017-03-16 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
|
US9394365B1
(en)
|
2014-03-12 |
2016-07-19 |
Yeda Research And Development Co., Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
|
WO2015145360A1
(en)
|
2014-03-24 |
2015-10-01 |
Glennie Martin J |
Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof
|
WO2015195163A1
(en)
|
2014-06-20 |
2015-12-23 |
R-Pharm Overseas, Inc. |
Pd-l1 antagonist fully human antibody
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
WO2016011069A1
(en)
|
2014-07-15 |
2016-01-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Medical uses of cd38 agonists (antibodies)
|
US10428146B2
(en)
|
2014-07-22 |
2019-10-01 |
Cb Therapeutics, Inc. |
Anti PD-1 antibodies
|
WO2016014799A1
(en)
|
2014-07-23 |
2016-01-28 |
University Of Iowa Research Foundation |
Epidermal growth factor and blockade of immune checkpoints in cancer immunotherapy
|
CN105330740B
(zh)
|
2014-07-30 |
2018-08-17 |
珠海市丽珠单抗生物技术有限公司 |
抗pd-1抗体及其应用
|
US9982053B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
GB201419084D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-PD-1 antibodies
|
US10822414B2
(en)
|
2014-11-11 |
2020-11-03 |
Sutro Biopharma, Inc. |
Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using anti-PD-1 antibodies
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
CA3175979A1
(en)
|
2014-12-22 |
2016-06-30 |
Pd-1 Acquisition Group, Llc |
Anti-pd-1 antibodies
|
CN107708732A
(zh)
|
2015-02-06 |
2018-02-16 |
卡德门企业有限公司 |
免疫调节剂
|
AR103726A1
(es)
|
2015-02-27 |
2017-05-31 |
Merck Sharp & Dohme |
Cristales de anticuerpos monoclonales anti-pd-1 humanos
|
MY188749A
(en)
|
2015-04-17 |
2021-12-28 |
Bristol Myers Squibb Co |
Compositions comprising a combination of nivolumab and ipilimumab
|
CN105061597B
(zh)
|
2015-06-09 |
2016-04-27 |
北京东方百泰生物科技有限公司 |
一种抗pd-1的单克隆抗体及其获得方法
|
EP3313883B1
(en)
|
2015-06-23 |
2023-12-06 |
Memorial Sloan Kettering Cancer Center |
Novel pd-1 immune modulating agents
|
EA201890285A1
(ru)
|
2015-07-13 |
2018-08-31 |
Сайтомкс Терапьютикс, Инк. |
Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
|
CN106699888B
(zh)
|
2015-07-28 |
2020-11-06 |
上海昀怡健康科技发展有限公司 |
一种pd-1抗体及其制备方法和应用
|
EP3328419B1
(en)
|
2015-07-30 |
2021-08-25 |
MacroGenics, Inc. |
Pd-1-binding molecules and methods of use thereof
|
AU2016303550B2
(en)
|
2015-08-04 |
2019-06-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
WO2017024515A1
(en)
|
2015-08-11 |
2017-02-16 |
Wuxi Biologics (Cayman) Inc. |
Novel anti-pd-1 antibodies
|
CA2993276A1
(en)
|
2015-08-11 |
2017-02-16 |
Yong Zheng |
Novel anti-pd-1 antibodies
|
CN107949573B
(zh)
|
2015-09-01 |
2022-05-03 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
LU92821B1
(en)
|
2015-09-09 |
2017-03-20 |
Mologen Ag |
Combination comprising immunostimulatory oligonucleotides
|
CN106999591B
(zh)
|
2015-09-28 |
2021-02-23 |
苏州盛迪亚生物医药有限公司 |
一种抗pd-1抗体制剂及其在医药上的应用
|
MX2018003689A
(es)
*
|
2015-09-29 |
2018-04-30 |
Celgene Corp |
Proteinas de union a pd-1 y metodos para usarlas.
|
WO2017058115A1
(en)
|
2015-09-29 |
2017-04-06 |
Asia Biotech Pte. Ltd. |
Pd-1 antibodies and uses thereof
|
UA123826C2
(uk)
|
2015-10-02 |
2021-06-09 |
Ф. Хоффманн-Ля Рош Аг |
Антитіла до pd1 та способи їх застосування
|
MY190324A
(en)
|
2015-10-02 |
2022-04-14 |
Symphogen As |
Anti-pd-1 antibodies and compositions
|
WO2017066561A2
(en)
|
2015-10-16 |
2017-04-20 |
President And Fellows Of Harvard College |
Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
|
CN107586342A
(zh)
|
2016-07-08 |
2018-01-16 |
生命序有限公司 |
重组免疫检查点受体及其应用
|
US10766958B2
(en)
|
2016-09-19 |
2020-09-08 |
Celgene Corporation |
Methods of treating vitiligo using PD-1 binding antibodies
|
JP2019531284A
(ja)
*
|
2016-09-19 |
2019-10-31 |
セルジーン コーポレイション |
Pd−1結合タンパク質を使用して免疫障害を治療する方法
|
AU2018246252A1
(en)
|
2017-03-29 |
2019-09-19 |
Celgene Corporation |
Formulations comprising PD-1 binding proteins and methods of making thereof
|
CN107137712A
(zh)
|
2017-05-09 |
2017-09-08 |
中山大学 |
Pd‑1h激动剂或拮抗剂的应用
|